Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Interested in finding short squeeze candidates? For ideas on where to look, we ran a screen you may find interesting.

We screened for stocks from the biotech industry for those that are highly shorted, with float shorts above 15%. We then screened for those with the support of hedge funds, with significant institutional purchases over the current quarter.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these names are candidates for a short squeeze? Use this list as a starting point for your own analysis.

1. Amyris Biotechnologies Inc. (NASDAQ:AMRS): Offers renewable compounds for a variety of markets. Float short at 18.18%. Net institutional purchases in the current quarter at 2.2M shares, which represents about 15.59% of the company's float of 14.11M shares.

2. Seattle Genetics Inc. (NASDAQ:SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Float short at 25.79%. Net institutional purchases in the current quarter at 11.4M shares, which represents about 10.05% of the company's float of 113.40M shares.

3. VIVUS Inc. (NASDAQ:VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Float short at 17.62%. Net institutional purchases in the current quarter at 13.9M shares, which represents about 24.44% of the company's float of 56.88M shares.

*Institutitonal data sourced from Fidelity, all other data sourced from Finviz.

Source: 3 Highly Shorted Biotech Stocks Being Bought Up By Hedge Funds